

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|------------------|
| Application Number | 10570849 |
| Filing Date | 2006-03-06 |
| First Named Inventor | Jamal Tazi |
| Art Unit | 1794 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | REGIM 3.3-085 |

| U.S.PATENTS | | | | | | Remove | | |
|--|---------|---|---------------------------|------------------------|---|--|--|--------------------------|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | | | | | | | |
| If you wish to add additional U.S. Patent citation information please click the Add button. | | | | | | Add | | |
| U.S.PATENT APPLICATION PUBLICATIONS | | | | | | Remove | | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | | | | | | | |
| If you wish to add additional U.S. Published Application citation information please click the Add button. | | | | | | Add | | |
| FOREIGN PATENT DOCUMENTS | | | | | | Remove | | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | 1 | | | | | | | <input type="checkbox"/> |
| If you wish to add additional Foreign Patent Document citation information please click the Add button | | | | | | Add | | |
| NON-PATENT LITERATURE DOCUMENTS | | | | | | Remove | | |
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | T ⁵ | |

| | | | |
|--|------------------------|------------------|------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10570849 |
| | Filing Date | | 2006-03-06 |
| | First Named Inventor | Jamal Tazi | |
| | Art Unit | | 1794 |
| | Examiner Name | Not Yet Assigned | |
| | Attorney Docket Number | REGIM 3.3-085 | |

| | | | |
|--|----|--|--------------------------|
| | 1 | SHARP, P.A. (1994). Split genes and RNA splicing. <i>Cell</i> 77, 805-815). | <input type="checkbox"/> |
| | 2 | MANLEY, J.L. AND TACKE, R. (1996). SR proteins and splicing control. <i>Genes Dev.</i> 10, 1569-1579. | <input type="checkbox"/> |
| | 3 | GRAVELEY, B.R. Sorting out the complexity of SR protein functions. <i>RNA</i> .2000. 6, 1197-1211. | <input type="checkbox"/> |
| | 4 | WANG, H.Y. et al., SC35 plays a role in T cell development and alternative splicing of CD45. <i>Mol.Cell</i> 2001. 7, 331-342. | <input type="checkbox"/> |
| | 5 | EWING, B. AND GREEN, P. Analysis of expressed sequence tags indicates 35,000 human genes. <i>Nat.Genet.</i> 2000. 25, 232-234. | <input type="checkbox"/> |
| | 6 | CARTEGNI, L. et al., Listening to silence and understanding nonsense: exonic mutations that affect splicing. <i>Nat.Rev. Genet.</i> 2002. 3, 285-298. | <input type="checkbox"/> |
| | 7 | NISSIM-RAFINIA, M. et al., Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. <i>Hum.Mol.Genet.</i> 2000. 9, 1771-1778; | <input type="checkbox"/> |
| | 8 | SAZANI, P. et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. <i>Nat. Biotechnol.</i> 2002. 20, 1228-1233. | <input type="checkbox"/> |
| | 9 | CARTEGNI, L. et al., Correction of disease-associated exon skipping by synthetic exon-specific activators. <i>Nat.Struct. Biol.</i> 2003. 10, 120-125. | <input type="checkbox"/> |
| | 10 | ANDREASSI, C. et al., Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. <i>Hum.Mol.Genet.</i> 2001.10, 2841-2849. | <input type="checkbox"/> |
| | 11 | LIU, X et al., Partial correction of endogenous DeltaF508 CFTR in human cystic . fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. <i>Nat.Biotechnol.</i> 2002. 20, 47-52. | <input type="checkbox"/> |

| | | | |
|--|------------------------|--|------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i> | Application Number | | 10570849 |
| | Filing Date | | 2006-03-06 |
| | First Named Inventor | | Jamal Tazi |
| | Art Unit | | 1794 |
| | Examiner Name | | Not Yet Assigned |
| | Attorney Docket Number | | REGIM 3.3-085 |

| | | | |
|--|----|---|--------------------------|
| | 12 | UEKAMA, K. et al., Cyclodextrins in drug carrier systems. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 1-40. | <input type="checkbox"/> |
| | 13 | PROCHIANTZ, A., Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr.Opin.Neurobiol. 1996. 6, 629-634 | <input type="checkbox"/> |
| | 14 | et VIVES, E. et al., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J.Biol.Chem. 1997. 272, 16010-16017. | <input type="checkbox"/> |
| | 15 | DOUGLAS, S.J. et al., Nanoparticles in drug delivery. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 233-261 Gregoriadis, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28. | <input type="checkbox"/> |
| | 16 | BLACK, D.L., Mechanisms of Alternative Pre-Messenger RNA Splicing. Annu.Rev.Biochem.2003. 72,291-336. | <input type="checkbox"/> |
| | 17 | GREGORIADIS, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28. | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.